Liver gene therapy by lentiviral vectors reverses anti‐factor IX pre‐existing immunity in haemophilic mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
A major complication of factor replacement therapy for haemophilia is the development of anti‐factor neutralizing antibodies (inhibitors). Here we show that liver gene therapy by lentiviral vectors (LVs) expressing factor IX (FIX) strongly reduces pre‐existing anti‐FIX antibodies and eradicates FIX inhibitors in haemophilia B mice. Concomitantly, plasma FIX levels and clotting activity rose to 50–100% of normal. The treatment was effective in 75% of treated mice. FIX‐specific plasma cells (PCs) and memory B cells were reduced, likely because of memory B‐cell depletion in response to constant exposure to high doses of FIX. Regulatory T cells displaying FIX‐specific suppressive capacity were induced in gene therapy treated mice and controlled FIX‐specific T helper cells. Gene therapy proved safer than a regimen mimicking immune tolerance induction (ITI) by repeated high‐dose FIX protein administration, which induced severe anaphylactoid reactions in inhibitors‐positive haemophilia B mice. Liver gene therapy can thus reverse pre‐existing immunity, induce active tolerance to FIX and establish sustained FIX activity at therapeutic levels. These data position gene therapy as an attractive treatment option for inhibitors‐positive haemophilic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 2×
“Recently, gene therapy was shown to provide a promising treatment for haemophilia B, by establishing long‐term expression of FIX in patients administered with a single i.v. dose of adeno‐associated viral (AAV) vectors expressing functional FIX (High, 2012; Nathwani et al, 2011).”
BackgroundB cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110 · cited 1×
“As a result, the de fi ciency or dysfunction of one of these factors impairs proper blood coagulation (Mannucci & Tuddenham, 2001).”
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Self-citationInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 1×
“Others and we have already shown that hepatocyte ‐ targeted expression of an Ag by different types of vectors favours the induction of tolerance mediated by Ag ‐ speci fi c Foxp3 þ Tregs (Annoni et al, 2009; Cao et al, 2007; Matrai et al, 2011; Mingozzi et al, 2003).”
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Self-citationCao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., & Herzog, R. W. (2007) · Blood · doi:10.1182/blood-2007-02-073304 · Cited by 220
Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288001 · Cited by 157
Mátrai, J., Cantore, A., Bartholomae, C. C., Annoni, A., Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., et al. (2011) · Hepatology · doi:10.1002/hep.24230 · Cited by 139
Self-citationEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
Cited by
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“Finally, hepatic gene transfer with microRNA (miRNA)-regulated LV vectors can similarly induce immune tolerance (see below).(105,106)”
BackgroundLiver-directed lentiviral gene therapy in a dog model of hemophilia B
Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1405 · Cited by 158
“In our prior studies of lentiviral vector gene therapy in mice with hemophilia B, we did not observe macroscopic liver lesions in the treated mice at necropsy (12, 14, 15).”
BackgroundSelf-citationEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
Pre-existing antibody: biotherapeutic modality-based review
Gorovits, B., Clements-Egan, A., Birchler, M., Liang, M., Myler, H., Peng, K., Purushothama, S., Rajadhyaksha, M., Salazar-Fontana, L., Sung, C., et al. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9878-1 · Cited by 85
Han, S.-O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., & Koeberl, D. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.010 · Cited by 78
“Subsequently, two groups showed that expression of coagulation factor IX could similarly induce immune tolerance following inhibitory antibody formation in mice with hemophilia.(21,22) Similar effects have been demonstrated following AAV vector administration in mice and dogs with hemophilia B using a high activity fa…”
BackgroundComplexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Development of gene transfer for induction of antigen-specific tolerance
Sack, B. K., Herzog, R. W., Terhorst, C., & Markusic, D. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.13 · Cited by 70
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
“Hepatic transgene expression occurs in an environment characterized by active downregulation of immune responses, thereby favoring induction of regulatory T cells and establishment of immune tolerance [8,44-49].”
BackgroundGene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
Gene therapy in an era of emerging treatment options for hemophilia B
Monahan, P. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12957 · Cited by 31
“platelet-targeted gene expression) or even eradicate pre-existing factor IX inhibitors (as has been demonstrated via hepatic expression following AAV or lentivirus factor IX gene delivery) [55] [56] [18] [49].”
BackgroundThe immune response to the fVIII gene therapy in preclinical models
Patel, S. R., Lundgren, T. S., Spencer, H. T., & Doering, C. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00494 · Cited by 29
“Inhibitor Eradication via Liver-Directed AAV-fVIII Gene Therapy? Recently, two independent groups demonstrated in a murine hemophilia B preclinical model that liver-directed AAV- or LV-fIX gene transfer can eradicate anti-fIX inhibitors and provide phenotypically-corrective plasma fIX activity (118, 126).”
BackgroundBiswas, M., Palaschak, B., Kumar, S. R. P., Rana, J., & Markusic, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01293 · Cited by 28
Metadata
- Authors
- Annoni, A., Cantore, A., Della Valle, P., Goudy, K., Akbarpour, M., Russo, F., Bartolaccini, S., D'Angelo, A., Roncarolo, M. G., & Naldini, L.
- Venue
- EMBO Molecular Medicine
- Published
- 2013-09-16
- Volume
- 5
- Issue
- 11
- Pages
- 1684-1697
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2129485351
- Cited by
- 58
- References
- 11
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.